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Pathologically expanded ‘peripheral’ B cell-helper T cells in rheumatoid 
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SUMMARY 1 
CD4+ T cells are central mediators of autoimmune pathology; however, the 2 
definition of their key effector functions in specific autoimmune diseases 3 
remains limited. Pathogenic CD4+ T cells within affected tissues may be 4 
identified by expression of markers of recent activation1. We applied this 5 
approach to joint tissue in rheumatoid arthritis (RA), a chronic immune-6 
mediated arthritis that affects up to 1% of the population2. Utilizing mass 7 
cytometry to detect activated T cells in RA synovial tissue revealed a 8 
strikingly expanded population of PD-1hi CXCR5- CD4+ T cells. These cells 9 
are not exhausted, Rather, multidimensional cytometry, transcriptomics, 10 
and functional assays define a population of PD-1hi CXCR5- ‘peripheral 11 
helper’ T (Tph) cells that express factors enabling B cell help, including IL-12 
21, CXCL13, ICOS, and MAF. Like PD-1hi CXCR5+ T ‘follicular helper’ (Tfh) 13 
cells, Tph cells induce plasma cell differentiation in vitro via IL-21 and 14 
SLAMF5-interactions3,4. However, global transcriptomics robustly separate 15 
Tph cells from Tfh cells, with altered expression of Bcl6 and Blimp-1 and 16 
unique expression of chemokine receptors that direct migration to inflamed 17 
sites, such as CCR2, CX3CR1, and CCR5, in Tph cells. Tph cells appear 18 
uniquely poised to promote B cell responses and antibody production 19 
within pathologically inflamed non-lymphoid tissues.   20 
We analyzed CD4+ T cells in 3 seropositive (defined as rheumatoid factor+ or 21 
anti-citrullinated peptide antibody+) RA synovial tissue samples with dense 22 
leukocyte infiltrates using a mass cytometry panel designed to interrogate both 23 
stromal and leukocyte populations (Extended Data Table 1). Two-dimensional 24 
visualization of the multidimensional cytometry data using the viSNE algorithm5 25 
revealed a heterogeneous CD4+ T cell population with distinct expression 26 
patterns of 5 commonly used activation markers (PD-1, MHC II, ICOS, CD69, 27 
CD38) (Fig. 1a). Strikingly, a large population of cells with high PD-1 expression 28 
clustered together in each of the 3 samples (Fig. 1a, Extended Data Fig. 1a). 29 
Biaxial gating of data from 6 seropositive RA synovial tissue samples confirmed 30 
high expression of PD-1 on ~25% of synovial CD4+ T cells, the majority of which 31 
co-expressed MHC II and/or ICOS (Fig. 1b, Extended Data Fig. 1b, Extended 32 
Data Table 2). 33 
 34 
In a complementary approach, 11-dimensional flow cytometric analysis of 35 
memory CD4+ T cells from paired synovial fluid and blood samples from 3 36 
seropositive RA patients also revealed a large population of synovial PD-1hi CD4+ 37 
T cells, a subset of which co-expressed MHC II and/or ICOS (Fig. 1c, Extended 38 
Data Table 3). Biaxial gating confirmed high PD-1 expression on ~30% of 39 
synovial fluid CD4+ T cells, mirroring results from synovial tissue (Fig. 1d,e, 40 
Extended Data Fig. 1c). The frequency of PD-1hi CD4+ T cell populations in 41 
seropositive RA synovial fluid (n=9) was over 5-fold higher than in synovial fluid 42 
from 19 patients with seronegative inflammatory arthritides (seronegative RA 43 
n=2, spondyloarthropathy n=8, juvenile idiopathic arthritis n=9, p<0.0001, Mann-44 
Whitney) (Fig. 1d,e).  45 
 46 
Because seropositive RA is characterized by autoantibody production and 47 
frequent synovial T cell-B cell aggregates6,7, we considered whether synovial PD-48 
1hi cells might be Tfh cells. Tfh cells, often identified as CXCR5+ PD-1+, are 49 
uniquely adapted to promote B cell recruitment and differentiation in lymph node 50 
follicles via production of IL-21, IL-4, CD40L, and CXCL13, the ligand for 51 
CXCR54. However, seropositive RA synovial tissue samples contained few PD-52 
1hi CXCR5+ Tfh cells (Fig. 1f,g), which clustered separately from PD-1hi CXCR5- 53 
cells in viSNE analyses (Fig. 1a, right panel). In contrast, ~85% of PD-1hi cells in 54 
synovial tissue lacked CXCR5, as did almost all PD-1hi cells in synovial fluid (Fig. 55 
1f,g). Measurement of CXCR5 transcript levels in sorted PD-1hi CXCR5- and PD-56 
1hi CXCR5+ cells from synovial tissue, synovial fluid, and blood confirmed that 57 
PD-1hi CXCR5- cells from all 3 sources contained little, if any, CXCR5 mRNA 58 
(Extended Data Fig. 1d,e). Thus, seropositive RA synovium contains abundant 59 
PD-1hi CD4+ T cells that are not Tfh cells.  60 
 61 
Intriguingly, PD-1hi CXCR5- CD4+ T cells with a similar multidimensional 62 
phenotype also appeared in the circulation, albeit at much lower frequencies 63 
(Fig. 1c, Extended Data Fig. 2a). Quantification of circulating PD-1hi CXCR5- 64 
memory CD4+ T cells in patients with established seropositive RA (n=42), 65 
seronegative RA (n=16), spondyloarthropathies (n=11), and non-inflammatory 66 
controls (n=35) demonstrated a significantly increased frequency of PD-1hi 67 
CXCR5- cells specifically in seropositive RA patients (Fig. 1h, Extended Data 68 
Fig. 2b, patient characteristics in Extended Data Table 2). PD-1hi MHC II+ 69 
CXCR5- and PD-1hi ICOS+ CXCR5- cells were also increased in blood of 70 
seropositive RA patients (Extended Data Fig. 2c). In contrast, the frequencies of 71 
PD-1hi CXCR5+ cells and cells with intermediate PD-1 expression were not 72 
increased (Extended Data Fig. 2d,e).  73 
 74 
PD-1hi CXCR5- cell frequencies were more robustly increased in seropositive RA 75 
patients with moderate or high disease activity (clinical disease activity index 76 
(CDAI)>10), compared to patients with low disease activity (CDAI≤10) (Fig. 1i). 77 
The frequency of PD-1hi CXCR5- cells did not vary with other clinical parameters 78 
such as age, sex, disease duration, use of methotrexate or biologic therapies, or 79 
serum anti-CCP antibody titer (Extended Data Fig. 2f-h). In an independent 80 
cohort of 23 seropositive RA patients assayed before and after starting a new RA 81 
medication, there was a significant correlation between reduction in disease 82 
activity and reduction in the frequency of PD-1hi CXCR5- T cells (Extended Data 83 
Fig. 2i). The frequency of PD-1hi CXCR5- cells, PD-1hi MHC II+ CXCR5- and PD-84 
1hi ICOS+ CXCR5- cells decreased significantly in the 18 patients whose disease 85 
activity improved after treatment escalation (Fig. 1j, Extended Data Fig. 2j).  86 
 87 
Since high PD-1 expression is often considered indicative of an exhausted 88 
state8,9, we assessed the function of synovial PD-1hi CXCR5- cells. Surprisingly, 89 
despite lack of CXCR5, PD-1hi CD4+ T cells sorted from seropositive RA synovial 90 
fluid showed >100-fold increased mRNA expression of IL-21 and >1000-fold 91 
increased expression of CXCL13, as well as higher levels of IFN-γ and IL-10, 92 
compared to PD-1- T cells, with the highest expression in PD-1hi MHC II+ cells 93 
(Fig. 2a, sorted as in Extended Data Fig. 1d). In contrast, IL-2 showed a trend 94 
towards lower expression in PD-1hi cells.  95 
 96 
Consistent with mRNA expression, PD-1hi CXCR5- cells sorted from RA synovial 97 
fluid more frequently produced IL-21 (~30%), but less frequently produced IL-2, 98 
compared to PD-1- or PD-1int cells, after stimulation with PMA+ionomycin (Fig. 99 
2b). Optimal CXCL13 production was detected after 24 hours of stimulation with 100 
anti-CD3/CD28 beads. Strikingly, at this timepoint, ~25% of PD-1hi CXCR5- cells 101 
produced CXCL13, but not IL-2, compared to <1% of PD-1- or PD-1int cells. High 102 
IL-21 and CXCL13 production by synovial fluid PD-1hi CXCR5- cells indicates that 103 
these cells are not globally exhausted, and instead suggested possible B cell-104 
helper function. 105 
 106 
In support of possible B cell helper-function, PD-1hi MHC II+ cells in seropositive 107 
RA synovial fluid also expressed high mRNA levels of the transcription factors 108 
MAF and BATF and the signaling adaptor SAP (encoded by SH2D1A). These 3 109 
factors are important for Tfh cell development or function (Fig. 2a)4. However, 110 
Bcl6, a transcription factor characteristically expressed in Tfh cells, was not 111 
elevated in synovial fluid PD-1hi cells, while Blimp-1, a transcription factor 112 
typically downregulated in Tfh cells, was upregulated4,10.  113 
 114 
Intracellular flow cytometry confirmed that Blimp-1 was significantly elevated in 115 
PD-1hi CXCR5- cells, but not PD-1hi CXCR5+ cells, from seropositive RA synovial 116 
samples (Fig. 2c). In contrast, Bcl6 was dramatically elevated in PD-1hi CXCR5+ 117 
cells, such that the Bcl6/Blimp-1 ratio was uniquely elevated in synovial PD-1hi 118 
CXCR5+ cells. Expression of MAF, a factor that promotes IL-21 production in 119 
human CD4+ T cells11, was elevated in both PD-1hi CXCR5- and PD-1hi CXCR5+ 120 
cells.  121 
 122 
PD-1hi CD4+ T cells from peripheral blood showed a transcriptional pattern similar 123 
to that in synovial fluid PD-1hi cells, with increased expression of IL-21, CXCL13, 124 
IFN-γ, MAF, SAP, and Blimp-1, but not IL-2 or Bcl6, in circulating PD-1hi MHC II+ 125 
cells compared to PD-1- cells (Extended Data Fig. 3a,b). Both PD-1hi CXCR5- 126 
and PD-1hi CXCR5+ cells expressed increased IL-21 and CXCL13 and 127 
decreased IL-2 compared to PD-1- T cells (Extended Data Fig. 3b). However, 128 
Blimp-1 expression was ~3-fold higher in blood PD-1hi CXCR5- cells compared to 129 
PD-1hi CXCR5+ cells, while Bcl6 expression was similar. Consistently, after in 130 
vitro stimulation, blood PD-1hi CXCR5- cells expressed more Blimp-1 and less 131 
Bcl6 protein than did PD-1hi CXCR5+ populations (Extended Data Fig. 3c). 132 
Taken together, these results indicate that both synovial and blood PD-1hi 133 
CXCR5- cells express factors associated with B cell-helper function without an 134 
elevated Bcl6/Blimp-1 expression ratio. 135 
 136 
To compare PD-1hi CXCR5- and PD-1hi CXCR5+ cells more broadly, we analyzed 137 
blood PD-1hi cells by mass cytometry (Extended Data Table 1). viSNE 138 
visualization of blood CD4+ T cells clustered PD-1hi CXCR5- and PD-1hi CXCR5+ 139 
cells in close proximity, indicating a similar multidimensional phenotype (Fig. 3a,  140 
Extended Data Fig. 4a). In contrast, FoxP3+ T regulatory cells aggregated in a 141 
separate region, indicating that most PD-1hi cells are not T regulatory cells, a 142 
finding confirmed by flow cytometry (Fig. 3a, Extended Data Fig. 4b). 143 
 144 
Both PD-1hi CXCR5- cells and PD-1hi CXCR5+ cells showed significantly 145 
increased expression of 11 proteins, including TIGIT, ICOS, CD38, and CD57, 146 
and significantly decreased expression of 5 proteins, including CD25 and CD127 147 
(Fig. 3b). Unlike TIGIT, additional inhibitory receptors TIM-3, LAG-3, and CTLA-4 148 
did not appear enriched on PD-1hi CXCR5- cells (Extended Data Fig. 4c). 149 
Compared to PD-1hi CXCR5+ cells, PD-1hi CXCR5- cells showed lower 150 
expression of CCR7 and CD27 but higher CD44 and T-bet (Fig. 3b, c), 151 
suggesting a potentially distinct migratory capacity12,13.  152 
 153 
We next performed an unbiased transcriptomic comparison of blood PD-1hi 154 
CXCR5- and PD-1hi CXCR5+ cell subpopulations by low-input RNA sequencing14. 155 
Principal components analysis (PCA) revealed that PD-1hi populations that co-156 
expressed ICOS and/or MHC II were similarly separated from PD-1- cells along 157 
the first principal component (PC1), irrespective of CXCR5 expression (Fig. 3d, 158 
gated in Extended Data Fig. 4d). However, PD-1hi CXCR5- and PD-1hi CXCR5+ 159 
cell populations were largely distinguished by the second principal component 160 
(PC2), indicating considerable differences in the global transcriptomes of PD-1hi 161 
CXCR5- cells and PD-1hi CXCR5+ cells beyond CXCR5 expression alone.  162 
 163 
Sixty-six genes were significantly differentially expressed when comparing all of 164 
the PD-1hi populations to the PD-1- populations (log fold change >1.2, FDR<0.01, 165 
Extended Data Table 4), including MAF, TIGIT, and SLAMF615,16. Analysis of a 166 
curated list of Tfh-associated genes15,17,18 demonstrated similar upregulation of 167 
multiple genes in the pooled PD-1hi CXCR5+ cell samples and PD-1hi CXCR5- 168 
cell samples (Fig. 3e), and hierarchical clustering of all 8 cell populations based 169 
on this gene list perfectly segregated all PD-1hi populations from PD-1- 170 
populations, regardless of CXCR5 expression (p<0.026, Extended Data Fig. 171 
4e). These results highlight a shared transcriptional program associated with B 172 
cell-helper function in PD-1hi CXCR5- cells and Tfh cells. 173 
 174 
However, we also identified 16 genes with significantly different expression 175 
between PD-1hi CXCR5- and PD-1hi CXCR5+ cells (Extended Data Table 5). 176 
Notably, PD-1hi CXCR5- cells showed 34-fold increased expression of CCR2, a 177 
chemokine receptor that mediates migration to sites of peripheral inflammation19. 178 
A targeted analysis of chemokine receptor expression on PD-1hi CXCR5- cells 179 
demonstrated striking upregulation of a set of ‘inflammatory’ chemokine 180 
receptors on these cells, including CCR2, CX3CR1, and CCR5, which was 181 
confirmed by flow cytometry (Fig. 3f,g)20. Notably, ~50% of PD-1hi CXCR5- cells 182 
in seropositive RA synovial fluid and synovial tissue expressed CCR2 (Fig. 3h). 183 
These results indicate that PD-1hi CXCR5- cells can be distinguished from PD-1hi 184 
CXCR5+ cells not only by the lack of CXCR5 but also by high expression of 185 
inflammatory chemokine receptors.  186 
 187 
To investigate the interconversion of PD-1hi cells that express distinct chemokine 188 
receptors, PD-1hi CXCR5- CCR2-, PD-1hi CXCR5- CCR2+, and PD-1hi CXCR5+ 189 
CCR2- cell populations sorted from blood were stimulated in vitro and re-190 
evaluated at different timepoints (Extended Data Fig. 5a,b). At day 2, CXCR5 191 
was transiently induced on both naïve and memory CD4+ T cell populations 192 
(Extended Data Fig. 5c), as previously described21. Interestingly, PD-1hi CCR2+ 193 
cells showed the most limited induction of CXCR5. By day 7, the majority of PD-194 
1hi cells that started out CXCR5- CCR2+ cells remained CCR2+, while less than 195 
5% of these cells expressed CXCR5 (Extended Data Fig. 5d). Conversely, most 196 
PD-1hi cells that started out CXCR5+ CCR2- remained CXCR5+, and less than 197 
5% of these cells acquired CCR2  These results demonstrate that even with 198 
powerful TCR stimulation, CXCR5 and CCR2 expression remain persistent, 199 
distinguishing features on PD-1hi in vitro.  200 
  201 
We next tested directly if PD-1hi CXCR5- CD4+ T cells can provide B cell help in 202 
vitro. PD-1hi CXCR5- cells sorted from seropositive RA synovial tissue or synovial 203 
fluid induced differentiation of co-cultured memory B cells into plasma cells, while 204 
CXCR5- cells without high PD-1 expression did not (Fig. 4a,b, sorted as in 205 
Extended Data Fig. 1d). The limited number of CXCR5+ T cells in synovial 206 
samples precluded comparison with PD-1hi CXCR5+ cells. PD-1hi CXCR5- cells 207 
from blood also induced memory B cell differentiation into plasma cells, with 208 
comparable activity in PD-1hi CXCR5- CCR2-, PD-1hi CXCR5- CCR2+, and PD-1hi 209 
CXCR5+ cells (Fig. 4b,c). PD-1hi CXCR5- cells from synovial fluid and blood also 210 
enhanced IgG production in the co-cultures (Fig. 4d). Neutralization of IL-21 211 
inhibited plasma cell differentiation induced by both blood PD-1hi CXCR5+ cells 212 
and PD-1hi CXCR5- cells by ~90% (Fig. 4e). Expression of SLAMF5, a factor 213 
important for T-B interactions,3 was elevated on both PD-1hi CXCR5- and PD-1hi 214 
CXCR5+ cells, and antibody blockade of SLAMF5, but not SLAMF6, completely 215 
abrogated plasma cell differentiation and IgG production (Fig. 4f, Extended Data 216 
Fig. 6a-c). Consistent with a link in vivo, RA treatment escalation reduced the 217 
frequency of circulating plasmablasts in parallel with the reduction in PD-1hi 218 
CXCR5- T cells (Fig. 1j). 219 
 220 
Finally, we evaluated the localization of PD-1hi T cells in RA synovium by 221 
immunofluorescence microscopy. CD3+ T cells with bright PD-1 staining were 222 
readily identified (Fig. 4g). CXCR5 appeared on CD20+ B cells and on a minority 223 
of PD-1hi T cells that were enriched within lymphoid aggregates (Fig. 4h,i). 224 
However, PD-1hi CXCR5- cells outnumbered PD-1hi CXCR5+ cells within 225 
lymphoid aggregates and were ~4-fold more abundant than PD-1hi CXCR5+ cells 226 
in regions outside of lymphoid aggregates (Fig. 4i). Within lymphoid aggregates, 227 
both PD-1hi CXCR5- cells and PD-1hi CXCR5+ cells were found adjacent to B 228 
cells (Fig. 4h,j). However, in areas outside of lymphoid aggregates, the majority 229 
of PD-1hi cells adjacent to B cells were CXCR5- (Fig. 4j, Extended Data Fig. 230 
6d). These results suggest a unique capacity of PD-1hi CXCR5- T cells to interact 231 
with B cells both within lymphoid aggregates and more diffusely throughout the 232 
inflamed synovium.  233 
 234 
Here we have defined a PD-1hi CXCR5- CD4+ Tph cell population markedly 235 
expanded in rheumatoid arthritis that combines B cell helper function with a 236 
migratory program targeting inflamed tissues. The abundance of Tph cells in RA 237 
synovium highlights the importance of tissue-localized T-B cell interactions22. Tph 238 
cells may infiltrate chronically inflamed tissues, which would not be expected to 239 
readily recruit Tfh cells, providing a potential mechanism for the initiation of 240 
ectopic lymphoid structures23-25. Tph cell production of CXCL13 and IL-21 may 241 
recruit both Tfh and B cells, promoting local autoantibody production that may not 242 
be reflected in serum, and perhaps modulating other B cell functions such as 243 
cytokine production7,26-28. Identification of the Tph cell phenotype considerably 244 
expands the spectrum of B cell-helper T cells that may be assessed as 245 
biomarkers for autoantibody-associated diseases. Further, high expression of 246 
PD-1 on Tph cells may offer a potential strategy for therapeutic targeting of tissue 247 
T cell-B cell interactions. 248 
  249 
 250 
  251 
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  Synovial Panel Blood cell Panel 
Metal Target Clone Target Clone 
89Y CD45 HI30   
 103Rh 
  
Live/Dead Cell-ID 
141Pr CD27 M-T271 CD27 M-T271 
142Nd CD19 HIB19 CD45RA HI100 
143Nd RANKL MIH24 CD44 BJ18 
144Nd CD64 10.1 CD39 A1 
145Nd CD16 3G8 CD16 3G8/B73.1 
146Nd CD8α RPA T8 CD8α RPA T8 
147Sm FAP Poly CD45RO UCHL1 
148Nd CD20 2H7 CD28 CD28.2 
149Sm CD45RO UCHL1 CD25 M-A251 
150Nd CD38 HIT2   
 151Eu PD-1 EH12.2H7 PD-1 EH12.2H7 
152Sm CD14 M5E2   
 153Eu CD69 FN50 CD69 FN50 
154Sm CXCR5 J252D4 CXCR5 J252D4 
155Gd CD4 RPA T4 CD4 RPA T4 
156Gd Podoplanin NC-08 CD73 AD2 
158Gd CD3 UCHT1 CD3 UCHT1 
159Tb CD11c Bu15 CD57 HCD57 
160Gd FcRL4 413D12 ICOS C398.4A 
161Dy CD138 MI15   
 162Dy CD90 5E 10 CXCR3 G025H7 
163Dy CCR2 K036C2   
 164Dy Cadherin11 23C6 CD161 HP-3G10 
165Ho FoxP3 PCH101 FoxP3 PCH101 
166Er CD34 581   
 167Er CD146 SHM-57 CD38 HIT2 
168Er IgA 9H9H11 CCR6 G034E3 
169Tm TCRγδ B1 CCR7 G043H7 
170Er ICOS C398.4A   
 171Yb CD66b G10F5 CD127 A019D5 
172Yb IgM MHM-88 CD122 TU27 
173Yb CD144 BV9 TIGIT MBSA43 
174Yb MHCII L243 HLA-DR L243 
175Lu IgD IA6-2 Tbet 4B10 
176Yb VCAM-1 STA Perforin dG9 
195Pt Live/Dead Cell-ID     
     Extended Data table 1. Mass cytometry panels for analysis of synovial and blood 
cells 
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Patient #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 
Synovial 
Tissue 
Donors 
Age 57 54 76 46 46 79 62 63 52 43 
Sex F F F F F F M M F F 
Disease Duration (yrs) 13 17 4 8 19 0.5 19 8 N/A N/A 
CDAI 14 9 17 15 21 25 5 9 N/A N/A 
CRP (mg/L) 25 8 8 11 17 19 13 66 76 0.8 
Methotrexate No Yes No No No No No Yes No No 
Biologic therapy Yes Yes Yes Yes Yes No No No No Yes 
Other synthetic 
DMARD Yes No Yes No Yes No No No Yes No 
 
Samples from patients 1-6 were used for mass and flow cytometry phenotyping.  
  
 
Samples from patients 7-10 were also included in flow cytometry phenotyping. 
   
  
  Control Seropositive 
RA 
Seronegative 
RA 
SpA 
Blood Cross-
sectional 
Cohort  
Number 35 42 16 11 
Age 61 ± 13 58 ± 14 58 ± 13 48 ± 12 
Female 22 (63) 33 (78) 11 (69) 5 (45) 
Disease Duration (yrs) N/A 13 ± 9 14 ± 10 10 ± 6 
C-reactive protein 
(mg/L) ND 9.3 ± 17.4 6.3 ± 8.5 3.9 ± 4.2 
CDAI ND 13.7 ± 8.1 9.8 ± 7.6 ND 
Methotrexate 0 19 (45) 8 (50) 2 (18) 
Anti-TNF 0 16 (38) 6 (38) 10 (90) 
Other biologics 0 10 (24) 5 (31) 0 
Other synthetic 
DMARDs 0 4 (10) 1 (6) 0 
Average ± SD are shown. Parentheses indicate proportion of patients. Other biologics include 
abatacept, rituximab, tocilizumab, tofacitinib. 
 
  
Improved Not 
Improved 
Blood 
Longitudinal 
Cohort 
Number 18 5 
Age 49 ± 17 57 ± 10 
Female 17 (94) 4 (80) 
CDAI Before  17.6 ± 9.3 21.7 ± 8.9 
CDAI After 6.3 ± 4.2 25.6 ± 10.2 
Started methotrexate 7 4 
Started anti-TNF 4 0 
Started other biologic 7 1 
Average ± SD are shown. Parentheses indicate proportion of patients.  
Extended Data table 2. Clinical characteristics of evaluated patients.  
 
 
 
 
  
Target Clone Fluorophore 
CD27 TB01 FITC 
CXCR3 CEW33D PE 
CD4 RPA-T4 PE-Cy7 
ICOS ISA-3 PerCP-Cy5.5 
CXCR5 J252D4 BV421 
CD45RA HI100 BV510 
HLA-DR G46-6 BV605 
CD49d 9F10 BV711 
PD-1 EH12.2H7 APC 
CD3 HIT3A AlexaFluor700 
CD29 TS2/16 APC-Cy7 
Live/Dead   Propidium iodide 
   Extended Data table 3. Flow cytometry panel for identifying PD-1hi 
cells 
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Gene logFC PD-1- Vs PD-1hi p-value 
adjusted p-
value 
PD-1 -6.394163674 1.03E-17 2.07E-13 
TOX -3.973939225 7.21E-13 7.21E-09 
ITM2A -1.206121015 4.54E-10 3.02E-06 
TIGIT -1.919479399 1.03E-09 5.15E-06 
MAF -1.424142776 4.43E-09 1.77E-05 
CA6 3.052456565 6.13E-09 2.04E-05 
CST7 -3.162619611 1.47E-08 3.80E-05 
SCML1 3.900002703 1.71E-08 3.80E-05 
SCO2 -5.202859453 1.67E-08 3.80E-05 
CDCA7 -4.502988841 2.56E-08 5.12E-05 
RAB37 -1.574133208 6.90E-08 0.000115075 
ICA1 -2.953123584 2.32E-07 0.000323551 
EZH2 -3.019907996 2.43E-07 0.000323551 
GZMK -2.753052708 2.68E-07 0.0003348 
MAP3K9 -2.362184122 4.44E-07 0.00052219 
PFN1 -1.46238995 7.05E-07 0.000704904 
SLAMF6 -1.241364005 8.88E-07 0.000817585 
EPSTI1 -2.040445226 8.99E-07 0.000817585 
NEFL 4.046814543 1.14E-06 0.00098964 
CHN1 -3.450144917 1.22E-06 0.001005063 
UBE2L6 -1.228575119 1.55E-06 0.001144629 
FANCI -2.790697425 1.77E-06 0.001264215 
PSMA4 -1.420908253 2.22E-06 0.001482222 
TOX2 -3.637770018 2.72E-06 0.001698657 
FABP5 -2.439672325 3.07E-06 0.001806205 
ANXA2 -1.269580271 3.38E-06 0.001932684 
CTLA4 -1.739000105 4.31E-06 0.002330776 
PLAG1 3.599551478 4.77E-06 0.002510472 
HVCN1 -3.516538014 5.08E-06 0.002605277 
FAM210A -2.782673649 5.37E-06 0.002683965 
ALOX5 3.436967858 5.88E-06 0.002799526 
RGS1 -1.204580998 6.09E-06 0.002834562 
MYL6B -3.072692168 8.27E-06 0.003651008 
CEP128 -3.16366403 8.18E-06 0.003651008 
ENC1 -3.605191323 8.40E-06 0.003651008 
MIS18BP1 -2.065611325 8.89E-06 0.003784483 
F5 -1.463762553 1.00E-05 0.004049502 
FN1 2.504688725 1.07E-05 0.004049502 
CXCR3 -3.01503276 1.06E-05 0.004049502 
ASB13 3.35115795 1.06E-05 0.004049502 
HIST2H2BF 3.678067821 9.85E-06 0.004049502 
PRR5L -2.171927479 1.10E-05 0.004078013 
KRT72 3.194468773 1.24E-05 0.004427712 
BZRAP1 -1.970565679 1.37E-05 0.004807752 
DUSP2 -1.459107208 1.55E-05 0.005330045 
DHFR -2.732987087 1.74E-05 0.005621497 
FBXO41 -2.405412912 1.94E-05 0.00614422 
CCDC86 -3.430212114 1.99E-05 0.00620599 
FCRL3 -1.770956334 2.06E-05 0.00627086 
AKR1C3 -3.308816301 2.07E-05 0.00627086 
SHMT2 -1.534205662 2.17E-05 0.006375986 
DDX54 -1.733666484 2.21E-05 0.006411258 
UBE2A -1.316870902 2.88E-05 0.007682071 
ANXA9 2.915422557 2.85E-05 0.007682071 
TUBB4B -1.239062048 3.12E-05 0.008096696 
TIMELESS -2.607726722 3.24E-05 0.008255379 
CCL5 -3.355363898 3.26E-05 0.008255379 
UQCRC1 -1.286406184 3.42E-05 0.008442364 
TBC1D4 -1.300326318 3.49E-05 0.008514635 
SYT11 -1.382472289 3.88E-05 0.009230883 
PMAIP1 -2.193153793 3.84E-05 0.009230883 
DIRC2 -2.784076776 4.00E-05 0.009304666 
SOX8 1.93871557 4.26E-05 0.009799307 
SPG20 1.801986978 4.50E-05 0.009899027 
DPP3 -1.957767214 4.39E-05 0.009899027 
DUSP4 -2.502643153 4.50E-05 0.009899027 
    Extended Data table 4. Significantly differentially expressed genes between PD-1- 
and PD-1hi cells  
 
  
Gene logFC PD-1hi CXCR5- vs PD-1hi CXCR5+ p-value 
adjusted p-
value 
RPL39 -1.234532087 1.42E-07 0.000230324 
LSP1 1.200685645 2.65E-07 0.00029438 
RPL34 -1.273114838 7.88E-07 0.000477468 
TTC4 4.631494115 1.29E-06 0.00063025 
LIME1 1.562056436 2.07E-06 0.000920442 
CCR2 5.094906534 2.25E-06 0.000957805 
ACTN4 2.323677525 2.83E-06 0.001130754 
CTSH 2.649046873 3.19E-06 0.001251255 
PLAC8 -1.351296215 6.85E-06 0.002360784 
GLIPR2 1.396871219 7.14E-06 0.00237986 
PRR5 2.819632034 1.02E-05 0.003057343 
RGS19 2.456286463 1.19E-05 0.003446459 
SAMD3 1.24882546 2.50E-05 0.006505926 
FOS -1.595174448 3.68E-05 0.008767004 
ANXA4 2.266594524 4.03E-05 0.009370528 
LTK 3.888867594 4.20E-05 0.009656997 
    Extended Data table 5. Significantly differentially expressed genes between PD-1hi 
CXCR5- cells and PD-1hi CXCR5+ cells  
 
  
METHODS 387 
Human subjects research 388 
Human subjects research was performed according to the Institutional Review 389 
Boards at Partners HealthCare, Hospital for Special Surgery, or the University of 390 
Birmingham Local Ethical Review Committee (Birmingham, UK) via approved 391 
protocols with appropriate informed consent as required. Patients with RA fulfilled 392 
the ACR 2010 Rheumatoid Arthritis classification criteria. Rheumatoid factor and 393 
anti-CCP antibody status, C-reactive protein level, and medication usage were 394 
obtained by review of electronic medical records. Biologic therapy was defined as 395 
use of anti-TNF, abatacept, rituximab, tocilizumab, or tofacitinib. Synovial tissue 396 
samples for mass and flow cytometry were collected from seropositive RA 397 
patients undergoing arthroplasty at the Hospital for Special Surgery, New York or 398 
at Brigham and Women’s Hospital, Boston. Samples with lymphocytic infiltrates 399 
on histology were prioritized for analyses. Synovial tissue for microscopy was 400 
acquired by synovial biopsy of a clinically inflamed joint from seropositive RA 401 
patients within the Birmingham early arthritis cohort (BEACON) at the University 402 
of Birmingham, UK.  403 
 404 
Synovial fluid samples were obtained as excess material from a separate cohort 405 
of patients undergoing diagnostic or therapeutic arthrocentesis of an 406 
inflammatory knee effusion as directed by the treating rheumatologist. These 407 
samples were de-identified; therefore, additional clinical information was not 408 
available, except for the 3 patients from whom paired synovial fluid and blood 409 
were obtained.  410 
  411 
Blood samples for clinical phenotyping were obtained from patients seen at the 412 
Brigham and Women’s Hospital Arthritis Center. For blood cell analyses in the 413 
cross-sectional cohort, CDAI was measured by the treating clinician on the day of 414 
sample acquisition. Anti-CCP titers were measured using the Immunoscan 415 
CCPLus ELISA (Eurodiagnostica), with a positive result defined as >25 units/mL. 416 
For RA patients followed longitudinally, a new treatment was initiated at the 417 
discretion of the treating physician, and CDAIs were determined at each visit by 418 
trained research study staff. Blood samples were acquired before initiation of a 419 
new biologic therapy or within 1 week of starting methotrexate. Concurrent 420 
prednisone at doses <10mg/day were permitted.  421 
 422 
All synovial fluid and blood samples were subjected to density centrifugation 423 
using Ficoll-Hypaque to isolate mononuclear cells, which were cryopreserved for 424 
batched analyses. Most phenotypic and transcriptomic analyses of blood T cells 425 
were performed on samples from both RA patients and non-inflammatory 426 
controls, with similar results unless specifically indicated. In vitro PD-1hi T cell 427 
interconversion assays and in vitro B cell helper-assays using blood T cells were 428 
performed using PBMC from blood bank leukoreduction collars from anonymous 429 
donors.   430 
 431 
All blood CD4+ T cell analyses included only CD45RA- memory CD4+ T cells 432 
except where naïve (CD45RA+) cells are specifically indicated. Here the term 433 
‘memory’ is used to denote an ‘antigen-experienced’ status indicated by loss of 434 
the naïve T cell marker CD45RA. This population includes both resting and 435 
activated antigen-experienced T cells. Synovial fluid and tissue analyses also 436 
utilize only memory CD4+ T cells unless total CD4+ T cells are indicated. Naïve T 437 
cells constituted <10% of the total population of CD4+ T cells in synovial tissue 438 
and synovial fluid.  439 
 440 
Synovial tissue analysis 441 
Synovial samples were acquired from discarded arthroplasty tissue. Synovial 442 
tissue was isolated by careful dissection, minced, and digested with 100μg/mL 443 
LiberaseTL and 100μg/mL DNaseI (both Roche) in RPMI (Life Technologies) for 444 
15 minutes, inverting every 5 minutes. Cells were passed through a 70μm cell 445 
strainer, washed, subjected to red blood cell lysis, and cryopreserved in Cryostor 446 
CS10 (BioLife Solutions) for batched analyses.  447 
 448 
Mass cytometry 449 
Cryopreserved disaggregated synovial cells or PBMCs were thawed into RPMI + 450 
10% FBS (HyClone). Viability was assessed with rhodium for PBMCs and 451 
cisplatin (both Fluidigm) for synovial cells. Cells were then washed and stained 452 
with primary antibody cocktails at 1:100 dilution (Extended Data Table 4). All 453 
antibodies were obtained from the Longwood Medical Area CyTOF Antibody 454 
Resource Core (Boston, MA). Cells were then washed, fixed and permeabilized 455 
using the Ebioscience Transcription Factor Fix/Perm Buffer for 45 minutes, 456 
washed in PBS/1%BSA/0.3% saponin, then stained for intracellular markers. 457 
Cells were re-fixed in formalin (Sigma), washed with Milli-Q water, and analyzed 458 
on a CyTOF2 for PBMC or Helios (Fluidigm) for synovial cells. Mass cytometry 459 
data were normalized using EQ™ Four Element Calibration Beads (Fluidigm) as 460 
described29.  461 
 462 
viSNE analyses were performed on cytometry data from 3 of 6 synovial tissue 463 
samples, 3 of 9 synovial fluid samples, and 8 of 14 blood samples using the 464 
Barnes-Hut SNE implementation on Cytobank (www.cytobank.org). All 3 465 
individual synovial tissue sample analyses are shown. For synovial fluid and 466 
blood cell analyses, one representative patient sample is shown. For synovial 467 
tissue mass cytometry data, gated CD4+ T cells were analyzed using all available 468 
protein markers, and each synovial tissue sample was analyzed individually to 469 
allow for maximal resolution. For paired synovial fluid-blood flow cytometry data, 470 
gated memory CD4+ T cells from synovial fluid and blood were analyzed together 471 
in a single viSNE analysis for direct comparison using an equal number of 472 
randomly selected cells from each sample. For blood mass cytometry analyses, 473 
equal numbers of gated memory CD4+ T cells from each sample were analyzed 474 
together using all markers except those used for gating (CD3, CD4, CD45RO). 475 
Comparison of marker expression on PD-1hi CXCR5- and PD-1hi CXCR5+ cells 476 
was performed with R-3.2 using permutation Wilcoxon rank-sum tests adjusted 477 
for multiple testing. For graphical representation of differential expression, mass 478 
cytometry data were transformed using the inverse hyperbolic sine30.   479 
 480 
Flow cytometry and cell sorting 481 
For phenotypic analyses, cryopreserved cells were thawed into warm RPMI/10% 482 
FBS, washed once in cold PBS, and stained in PBS/1% BSA with antibody mixes 483 
as in Extended Data Table 2 for 45 minutes. Additional antibodies used include 484 
SLAM-AF488 (A12), SLAMF5-PE (CD84.1.21), SLAMF6-PE (NT-7), CCR2-PE 485 
(K036C2), CX3CR1-FITC (2A9-1), CD38-PE (HIT2), CD138-PE/Cy7 (MI15), 486 
CTLA4-PerCP/Cy5.5 (L3D10) from BioLegend, CCR5-FITC (2D7) and FoxP3-487 
AF647 (236A/E7) from BD Biosciences, LAG-3-APC from R&D Systems, TIM-3-488 
PE/Cy7 (F38-2E2) and TIGIT-PE (MBSA43) from eBioscience.  489 
 490 
Cells were washed in cold PBS, passed through a 70-micron filter, and data 491 
acquired on a BD FACSAria Fusion, BD Fortessa, or BD Canto II analyzer using 492 
FACSDiva software. Data were analyzed using FlowJo 10.0.7. For blood cell 493 
quantification in Figure 2, samples were analyzed in uniformly processed batches 494 
of coded samples with multiple disease conditions included in each batch. Upon 495 
data acquisition, disease categories were assigned to data files. A single set of 496 
gates for PD-1, CXCR5, ICOS, and MHC II was applied to all samples. The 497 
percentage of PD-1hi T cell populations among memory CD4+ T cells populations 498 
and the percentage of plasmablasts (CD19+ CD20lo CD38hi CD27+) among total 499 
CD19+ B cells were calculated for indicated samples.  500 
 501 
T cells were sorted directly from synovial fluid and synovial tissue samples. For 502 
sorting blood T cells, total CD4+ T cells were first isolated by magnetic bead 503 
negative selection (Miltenyi Biotec). Cell sorting was performed on a BD 504 
FACSAria Fusion sorter using a 70 micron nozzle. Sort gates were drawn as 505 
depicted in Extended Data Fig. 1d. Cell purity was routinely >98%. For 506 
functional analyses, cells were sorted into cold RPMI/10% FBS. For RNA 507 
analyses, sorted cells were lysed in RLT lysis buffer (Qiagen) with 1% β-508 
mercaptoethanol (Sigma). 509 
 510 
Intracellular cytokine staining 511 
Synovial fluid mononuclear cells were stained with anti-PD-1-PE/Dazzle 594, 512 
CXCR5-BV605, and CD4-BV650 (Biolegend), and propidium iodide. CXCR5- PD-513 
1hi, PD-1int, and PD-1- CD4+ T cells sorted as above were pelleted by 514 
centrifugation and resuspended in RPMI/10% FBS at a density of 5x105 cells/mL 515 
in 24-well plates. Cells were stimulated with either anti-CD3/anti-CD28 beads at 516 
a ratio of 2:1 (cell:bead) for 24 hours, or with PMA (50ng/mL) and ionomycin 517 
(1μg/mL). Brefeldin A and monensin (both 1:1000, eBioscience) were added for 518 
the last 5 hours. Cells were washed twice in cold PBS, incubated for 30 minutes 519 
with Fixable Viability Dye eFluor 455UV (eBioscience), washed in PBS/1%BSA, 520 
and then fixed and permeabilized using the eBioscience Transcription Factor 521 
Fix/Perm Buffer. Cells were washed in PBS/1%BSA/0.3% saponin and incubated 522 
with IL-21-APC (3A3-N2), IL-2-PE/Cy7 (MQ1-17H12), and CXCL13-AF700 523 
(53610, R&D Systems) for 30 minutes, washed once, filtered, and data acquired 524 
on a BD Fortessa analyzer. 525 
     526 
Intracellular transcription factor staining 527 
Synovial tissue and synovial fluid cells were thawed, washed twice in PBS, and 528 
incubated with Fixable Viability Dye eFluor 455UV (eBioscience) for 30 minutes. 529 
Cells were then washed in PBS/1%BSA and stained with antibodies against 530 
surface markers anti-CD3-AF700, anti-CD4-BV650, anti-CCR2-PE, anti-CXCR5-531 
BV421, anti-PD-1-PE/Dazzle 594 (all Biolegend) for 30 minutes. Cells were 532 
washed once and incubated with eBioscience Transcription Factor Fix/Perm 533 
Buffer. Cells were washed in PBS/1%BSA/0.3% saponin and incubated in 534 
intracellular antibodies anti-MAF-PerCP-eFluor710 (sym0F1, eBioscience), anti-535 
Bcl6-APC (BCL-UP, eBioscience), and anti-Blimp-1-AF488 (646702, R&D 536 
Systems) at 1:20 dilutions for 4 hours. Cells were washed once, filtered, and data 537 
acquired on a BD Fortessa analyzer. Intracellular detection of FoxP3 and CTLA-4 538 
were performed by the same method on magnetic-bead purified blood CD4+ T 539 
cells using the indicated surface markers.  540 
 541 
RT-PCR analyses 542 
RNA isolated using RNeasy Micro Kits (Qiagen). cDNA was prepared using 543 
Quantitect RT-PCR (Qiagen) and PCR performed with Brilliant III SYBRGreen on 544 
an a Stratagene Mx3000. Primers used were as follows: RPL13A (Forward: 5’-545 
CATAGGAAGCTGGGAGCAAG-3’; Reverse: 5’-GCCCTCCAATCAGTCTTCTG-3’), IL-2 546 
(Forward: 5’-AGAACTCAAACCTCTGGAGGAAG-3’; Reverse: 5’-547 
GCTGTCTCAGCATATTCACAC-3’), IFN-γ (Forward: 5’-GCATCGTTTTGGGTTCTCTTG-3’; 548 
Reverse: 5’-AGTTCCATTATCCGCTACATCTG-3’), IL-10 (Forward: 5’-549 
CGCATGTGAACTCCCTGG-3’; Reverse: 5’-TAGATGCCTTTCTCTTGGAGC-3’), IL-21 550 
(Forward: 5’-AGGAAACCACCTTCCACAAA-3’; Reverse: 5’-551 
GAATCACATGAAGGGCATGTT-3’), CXCL13 (Forward: 5’-TCTCTGCTTCTCATGCTGCT-3’; 552 
Reverse: 5’-TCAAGCTTGTGTAATAGACCTCCA-3’), PD-1 (Forward: 5’-553 
CCAGGATGGTTCTTAGACTCC-3’; Reverse: 5’-TTTAGCACGAAGCTCTCCGAT-3’), CXCR5 554 
(Forward: 5’-GGGAGCCTCTCAACATAAGAC-3’; Reverse: 5’-555 
CCAATCTGTCCAGTTCCCAGA-3’), MAF (Forward: 5’-CCGTCCTCTCCCGAGTTTTT-556 
3’; Reverse: 5’-TGCTGGGGCTTCCAAAATGT-3’), Bcl6 (Forward: 5’-557 
GTTTCCGGCACCTTCAGACT-3’; Reverse: 5’-CTGGCTTTTGTGACGGAAAT-3’), BATF 558 
(Forward: 5’-TGGCAAACAGGACTCATCTG-3’; Reverse: 5’-CTGTTTCTCCAGGTCTTCGC-559 
3’), SAP (Forward: 5’-GCTATTTGCTGAGGGACAGC-3’; Reverse: 5’-560 
TGTCTGGGACACTCGGTATG-3’), Blimp-1 (Forward: 5’-AACTTCTTGTGTGGTATTGTCGG-561 
3’; Reverse: 5’-TCTCAGTGCTCGGTTGCTTT-3’). Expression levels relative to control 562 
gene RPL13A were calculated.  563 
 564 
RNA sequencing 565 
RNA was isolated from 800-1000 cells from sorted T cell subpopulations as 566 
described. 5uL of total RNA were placed in wells of a 96-well plate and RNA 567 
sequencing libraries were prepared at Broad Technology Labs at the Broad 568 
Institute of Harvard and MIT using the Illumina SmartSeq2 platform. Samples 569 
were sequenced on a NextSeq500 using 75bp paired-end reads to an average 570 
depth of 9M pairs of reads per sample. All cDNA transcripts from Ensembl 571 
release 82 were quantified with Kallisto version 0.42.431. We used limma to 572 
model each gene as a linear combination of donor-specific effects. The residuals 573 
from these models were tested by ANOVA across 8 gates, and 581 genes with a 574 
significant F statistic with <5% FDR were selected for PCA. Heatmaps show row-575 
normalized relative gene expression z-scores across columns (mean 0 and 576 
variance 1), with subpopulations of PD-1hi CXCR5- or PD-1hi CXCR5+ averaged 577 
to yield overall PD-1hi CXCR5- and PD-1hi CXCR5+ expression values. In 578 
comparisons of specific cell populations, genes with log fold change >1.2 and 579 
FDR <1% were considered differentially expressed. 580 
 581 
PD-1hi cell in vitro stimulation assays  582 
CD4+ T cells were purified from PBMCs from leukoreduction collars by magnetic 583 
bead negative selection and stained with anti-CD4-BV650, anti-CD45RA-BV510, 584 
anti-PD-1-APC, anti-CXCR5-BV605, and anti-CCR2-PE/Cy7. Naïve CD4+ T cells 585 
and memory CD4+ T cell subpopulations were sorted into RPMI/10% FBS. 586 
50,000 cells were resuspended in RPMI/10%FBS at 0.25 x 106 cells/mL and 587 
cultured with anti-CD3/CD28 beads (Dynabeads) at a cell:bead ratio of 5:1 for 2 588 
or 7 days. Cells were then either re-stained with anti-PD-1-PE and anti-CXCR5-589 
BV421 antibodies and sorted into lysis buffer for RT-PCR analyses, or stained 590 
with CCR2-PE and CXCR5-BV421 and analyzed by intracellular flow cytometry 591 
for transcription factors as above.  592 
 593 
T cell-B cell co-cultures 594 
Total B cells were isolated first from PBMCs from blood bank leukoreduction 595 
collars by magnetic bead positive selection using CD19 (Miltenyi), then CD4+ T 596 
cells were isolated by negative selection. B cells were stained with CD14-APC, 597 
CD3-PeCy7, and CD27-BV510 (all from Biolegend), and memory B cells sorted 598 
as CD27+ CD14- CD3- cells on a BD FACSAria Fusion to remove contaminating 599 
T cells and monocytes. Sorted T cell populations were co-cultured with 600 
autologous memory B cells at a ratio of 1:10 in 100uL of RPMI/10%FBS and 601 
stimulated with LPS (5μg/mL) and SEB (1μg/mL) for 7 days. For co-cultures 602 
using synovial tissue or synovial fluid T cells, allogeneic memory B cells from 603 
PBMC were used. Supernatants were collected and total IgG measured by 604 
ELISA (eBioscience). Cells were harvested and analyzed by flow cytometry, with 605 
plasmablasts defined as CD19+ CD20low CD38hi CD27+ and plasma cells defined 606 
as CD19+ CD20low CD38hi CD27+ CD138+. For blocking experiments, 10μg/ml 607 
anti-SLAMF5 or anti-SLAMF6 antibodies (Biolegend) or 20μg/mL IL-21R-Ig (R&D 608 
Systems) were used. 609 
 610 
Immunofluorescence microscopy 611 
6 micron sections of synovium frozen in OCT were fixed in acetone, rehydrated 612 
in PBS, and blocked with 10% normal goat serum prior to application of primary 613 
antibodies as follows: PD-1 (EH12.2H7, BioLegend), CD3 (SP7, Abcam), CD20 614 
(L26, Dako), CXCR5 (MAB190, R&D Systems), all at a dilution of 1:100 except 615 
for CD20, which was used at 1:300. All secondary antibodies were raised in goat. 616 
CXCR5 was detected using anti mouse IgG2b biotin (Southern biotech) followed 617 
by streptavidin conjugated AlexaFluor 546 (Life Technologies), CD20 with anti-618 
mouse IgG2a FITC (both Southern Biotech), PD-1 with anti-mouse IgG1 619 
conjugated to AlexaFluor 647 and CD3 with anti-rabbit AlexaFluor 546 (both Life 620 
Technologies). FITC staining was amplified with anti-FITC AlexaFluor 488 (Life 621 
Technologies). Slides were mounted using ProLong Diamond (Life 622 
Technologies), left to cure overnight and imaged using a Zeiss LSM 780 confocal 623 
microscope. Images were processed using Zen Black (Zeiss) and then ImageJ. 624 
Cell counts were performed on images obtained from confocal imaging using the 625 
Cell Counter plugin for ImageJ (imagej.net/Cell_Counter). Synovial regions were 626 
categorized as ‘lymphoid aggregates’ when the B cells and T cells formed distinct 627 
clusters, and ‘diffusely infiltrated’ when B cells were loosely distributed within the 628 
synovium. 629 
 630 
Statistical analyses 631 
 632 
Statistical tests were performed as indicated in figure legends using two-sided 633 
tests. Dunn’s test was used for multiple comparisons in non-parametric tests and 634 
Bonferroni test for ANOVA. P-values <0.05 were considered significant.  635 
 636 
36 Finck, R. et al. Normalization of mass cytometry data with bead standards. 
Cytometry. Part A : the journal of the International Society for Analytical 
Cytology 83, 483-494, doi:10.1002/cyto.a.22271 (2013). 
37 Finak, G., Perez, J. M., Weng, A. & Gottardo, R. Optimizing 
transformations for automated, high throughput analysis of flow cytometry 
data. BMC bioinformatics 11, 546, doi:10.1186/1471-2105-11-546 (2010). 
38 Bray, N. P., H.; Melsted, P.; Pachter, L. . Near-optimal RNA-Seq 
quantification. arXiv 1505, 02710v02712 (2015). 
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FIGURE LEGENDS: 
 
Figure 1: Expanded PD-1hi CXCR5- CD4+ T cells in joints and blood of 
seropositive RA patients. 
a) viSNE plots of RA synovial tissue total CD4+ T cells analyzed by mass 
cytometry. Color indicates cell expression level of labeled marker. Dotted circle 
indicates PD-1hi cells. Arrow indicates CXCR5+ cells. b) PD-1hi T cell frequency in 
RA synovial tissue by mass cytometry (n=6). c) viSNE plots of paired RA synovial 
fluid and blood memory CD4+ T cells. d) Flow cytometric detection of synovial 
fluid PD-1hi CD4+ T cells. e) PD-1hi CD4+ T cell frequency in synovial fluid from 
seropositive RA (n=9) and seronegative inflammatory arthritides (n=19). f) Flow 
cytometry for PD-1 and CXCR5 on memory CD4+ T cells. g) Frequency of PD-1hi 
cells in seropositive RA synovial fluid (n=9) and tissue (n=10). h) Frequency of 
PD-1hi CXCR5- cells in seropositive RA (n=42), seronegative RA (n=16), 
spondyloarthropathies (SpA, n=11), and control (n=35) patient blood. i) PD-1hi 
frequency in seropositive RA patients with low (n=14) or moderate-high (n=28) 
disease activity. j) PD-1hi CD4+ T cell and plasmablast frequencies before and 
after RA treatment escalation (n=18). Mean ± SD in b,e,g, median ± interquartile 
range in h,i shown. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 by Mann-
Whitney (e,g), Kruskal-Wallis (h,i), Wilcoxon test (j). 
 
Figure 2: Synovial PD-1hi CXCR5- CD4+ T cells express factors associated 
with B cell help. 
a) RT-PCR for cytokines (n=7 donors) and intracellular regulators (n=5 or 6 
donors) in T cell populations from seropositive RA synovial fluid. Median ± 
interquartile range. b) Flow cytometric quantification of IL-21, IL-2, and CXCL13 
production by stimulated synovial CD4+ T cell (n=3 experiments using different 
donors). c) Flow cytometric quantification of transcription factor expression in 
CD4+ T cells from RA synovial fluid (blue, n=3 donors) or synovial tissue (green, 
n=3 donors). For b,c, mean ± SD shown. * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001 by Friedman’s test compared to PD-1- MHC II- cells (a) or one-way 
ANOVA comparing PD-1- CXCR5-, PD-1hi CXCR5-, and PD-1- CXCR5+ (c). 
 
Figure 3: High dimensional analyses of PD-1hi CXCR5- and PD-1hi CXCR5+ 
cells identify shared and distinct features. 
a) viSNE plots of blood memory CD4+ T cells from a representative RA patient. 
Circle indicates PD-1hi cells. b) Transformed median expression difference of 
significantly altered proteins between PD-1hi populations and PD-1- CXCR5- 
memory CD4+ T cells (n=14 RA patients). c) Median expression of indicated 
proteins (n=7 RA patients (black) and 7 controls (grey)). d) PCA of RNA-seq 
transcriptomes (n=4 donors). e,f) Heatmap of expression of Tfh-associated 
genes (e) or chemokine receptors (f) by RNA-seq. g) Flow cytometric 
quantification of chemokine receptor expression on blood memory CD4+ T cells. 
h) CCR2 expression on PD-1hi CXCR5- CD4+ T cells in RA synovial samples 
(tissue n=10, fluid n=5). For c,g,h, mean ± SD shown. * p<0.01, ** p<0.001, *** 
p<0.0001 Wilcoxon test. 
 Figure 4: PD-1hi CXCR5- cells promote plasma cell differentiation via IL-21 
and SLAMF5 interactions. 
a) Flow cytometric detection of plasma cells. b) Plasma cell frequency in co-
cultures of memory B cells with indicated T cell populations from indicated 
sources.  
Pooled data from 2 experiments (synovial tissue, n=3 replicates per experiment), 
3 experiments (synovial fluid), or 6 experiments (blood) using different donors. c) 
Co-cultures using blood T cell subpopulations as in (b). d) Total IgG in 
supernatants of co-cultures as in (b). e,f) Co-cultures as in (b) with IL-21R-Ig 
fusion protein (e) or anti-SLAMF5/SLAMF6 antibody (f). For c-f) 1 of 3 
experiments with different donors (n=3 replicates) shown. g,h) 
Immunofluorescence microscopy of RA synovium showing PD-1hi CXCR5- cells 
(white arrow) and PD-1hi CXCR5+ cell (gray arrow). Scale bar = 50 microns. i,j) 
Quantification of PD-1hi cells (i) and PD-1hi cells adjacent to B cells (j) in RA 
synovium (n=5-8 HPF from 4 samples). Means ± SD shown. * p<0.05, ** p<0.01, 
*** p<0.001 Mann-Whitney (b, synovial tissue), Kruskal-Wallis compared to PD-1- 
CXCR5- (b,c,e,f), or Wilcoxon (g).  
 
Extended Data Figure 1: Detection of PD-1hi CD4+ T cells in RA synovial 
tissue and fluid by mass and flow cytometry. 
a) viSNE plots of mass cytometry data on CD4+ T cells as in Fig. 1a from two 
additional seropositive RA synovial tissue samples. b) Gating strategy to identify 
synovial tissue PD-1hi CD4+ T cell populations by mass cytometry. c) Gating 
strategy to identify synovial fluid PD-1hi memory CD4+ T cells by flow cytometry. 
d) Examples of gating used to sort memory CD4+ T cell populations from patient 
samples. e) Detection of CXCR5 mRNA by RT-PCR in sorted memory CD4+ T 
cell populations from synovial tissue (n=3 donors, 2 of which provided sufficient 
PD-1hi CXCR5+ cells for analysis), synovial fluid (n=3 donors, 1 of which provided 
sufficient PD-1hi CXCR5+ cells for analysis), and blood (n=2 donors). Purple 
boxes indicate PD-1- and PD-1hi CXCR5+ cells sorted from human tonsil as 
controls. Lines in (e) indicate mean for synovial or blood samples. 
 
Extended Data Figure 2: PD-1hi CXCR5- CD4+ T cells are expanded in 
circulation of patients with active, seropositive RA and decrease with 
response to therapy. 
a) Mean expression of MHC II and ICOS in memory CD4+ T cell populations 
defined by PD-1 and CXCR5 expression from synovial tissue (n=10), synovial 
fluid (n=9), and blood (n=42) from seropositive RA patients. Mean ± SD shown. 
b) Flow cytometric detection of PD-1 and CXCR5 expression on blood memory 
CD4+ T cells. c) Frequency of PD-1hi CXCR5+ cells within circulating memory 
CD4+ T cells in patients with seropositive RA (RA Ab+, n=42), seronegative RA 
(RA Ab-, n=16), spondyloarthropathies (SpA, n=11), and non-inflammatory 
control patients (control, n=35) as in Fig. 1h. d,e) Frequency of PD-1hi 
subpopulations that co-express MHC II or ICOS (d) or with intermediate PD-1 
expression (e) in patients as in (c). f) Correlation between age or disease 
duration and circulating PD-1hi CXCR5- CD4+ T cells in all seropositive patients 
for which data was available (n=38). g) PD-1hi CXCR5- T cell frequencies in 
seropositive RA patients segregated based on sex or medication usage (n=38). 
h) Correlation between serum anti-CCP antibody titer and circulating PD-1hi 
CXCR5- CD4+ T cell in all RA patients (n=53, black line, p=0.0049) or in only anti-
CCP antibody+ patients (n=29, green line, p=0.48). i) Correlation between fold 
change in CDAI and fold change in PD-1hi CXCR5- T cell frequency patients 3 
months after addition of a new RA medication (n=23; methotrexate=11, anti-
TNF=4, abatacept=4, tocilizumab=2, tofacitinib=2). j) Frequency of PD-1hi T cell 
subpopulations before and after RA treatment escalation in 18 patients with 
reduced disease activity after therapy. Median ± interquartile range in c,d,e, and 
mean ± SD in a,g is shown. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 by 
Kruskal-Wallis (c,e), Mann-Whitney (d,g), Wilcoxon test (j). In f,h,i p-values 
calculated by Spearman correlation.  
  
Extended Data Figure 3: Blood PD-1hi CXCR5- CD4+ T cells express factors 
associated with B cell help.  
a) mRNA expression levels of cytokines/chemokines (n=10 donors, 6 RA patients 
(black), 4 controls (grey)) or transcription factors/signaling molecules (n=4 or 5 
donors) detected by RT-PCR in sorted circulating memory CD4+ T cell 
populations, normalized to RPL13A. Median ± interquartile range shown. * 
p<0.05, ** p<0.01, *** p<0.001 Friedman’s test, compared to PD-1- MHCII- group. 
b) Cytokine and transcription factor mRNA expression in blood PD-1hi CD4+ T 
cell populations divided according to CXCR5 expression, relative to PD-1- 
memory CD4+ T cells (n=6 donors). Mean ± SD shown. c) Flow cytometric 
quantification of of Bcl6 and Blimp-1 in PD-1hi memory CD4+ T cell 
subpopulations sorted according to chemokine receptor expression, then 
stimulated in vitro for 2 days with anti-CD3/CD28 beads. Representative data 
from 1 of 3 experments using cells from different donors.  
 
Extended Data Figure 4: Identification and characterization of circulating 
PD-1hi CXCR5- and PD-1hi CXCR5+ in mass cytometry and RNA-seq 
analyses. 
a) Gating of blood PD-1hi memory CD4+ T cells in mass cytometry analyses. b) 
Flow cytometric detection of FoxP3 and PD-1 in blood memory CD4+ T cells from 
RA patients (black circles, n=5) and controls (grey circles, n=3). * p<0.05, 
**p<0.001 Kruskal-Wallis test compared to PD-1- cells. c) Flow cytometric 
detection of inhibitory receptors on blood memory CXCR5- CD4+ T cells. Data 
from 1 of 3 RA patients with similar results. d) Sort strategy for PD-1hi CXCR5- 
and PD-1hi CXCR5+ cell populations for RNA-seq. e) Hierarchical clustering of T 
cell subsets sorted as in (d), with clustering based on expression of Tfh-
associated genes measured in RNAseq transcriptomes.  
 
Extended Data Figure 5: Limited interconversion of PD-1hi CCR2+ and PD-
1hi CXCR5+ T cells in vitro. 
a) Flow cytometry of CXCR5 and CCR2 on gated PD-1hi CD4+ cells from blood. 
b) Expression of CXCR5 and CCR2 on indicated sorted PD-1hi T cell populations 
7 days after in vitro stimulation with anti-CD3/CD28 beads. c,d) Percentage of 
cells from each sorted PD-1hi population that expressed CXCR5 or CCR2 on day 
2 (c) or day 7 (d) after in vitro stimulation. Naive CD4+ T cells are shown as 
control. Mean ± SD shown (n=3 donors from 3 separate experiments).  
 
Extended Data Figure 6: SLAMF5 is required for B cell-helper function of 
PD-1hi CXCR5- CD4+ T cells. 
a) Flow cytometric quantification of SLAM, SLAMF5, and SLAMF6 expression on 
memory CD4+ T cells (n=10 donors, 5 RA patients, 5 controls). b) Quantification 
of frequency of memory B cells with plasma cell markers after co-culture with PD-
1hi CXCR5+ CD4+ T cells with addition of blocking antibodies against SLAMF5 
and/or SLAMF6. c) IgG quantification by ELISA in co-cultures of memory B cells 
with PD-1hi CXCR5- or PD-1hi CXCR5+ CD4+ T cells with addition of blocking 
antibodies against SLAMF5 and/or SLAMF6. For b,c) 1 of 3 experiments with 
similar results (n=3 replicates shown). Mean ± SD shown. * p<0.05, ** p<0.01, *** 
p<0.001 Kruskal-Wallis compared to PD-1- CXCR5- (a) or isotype control (b,c). d) 
Immunofluorescence microscopy of CD20 (green), CXCR5 (red), and PD-1 
(blue), in seropositive RA synovial tissue. Arrows point to PD-1hi CXCR5- cells 
adjacent to B cells. Scale bar = 50 microns. 
 
